By a News Reporter-Staff News Editor at Diabetes Week -- Current study results on Diet and Nutrition have been published. According to news originating from Tehran, Iran, by NewsRx correspondents, research stated, "Given the long term benefits observed with metformin use in diabetes patients, a role in modulating oxidative stress is imputable. Effects of metformin on markers of oxidative stress, antioxidant reserve, and HDL-c associated antioxidant enzymes were investigated."
Our news journalists obtained a quote from the research from the Shaheed Beheshti University of Medical Sciences, "In a clinical trial setting (Registered under Clinical Trials.gov Identifier no. NCT01521624) 99 medication-naive, newly diagnosed type 2 diabetes patients were randomly assigned to either metformin or lifestyle modification. AOPP, AGE, FRAP, activities of LCAT, and PON were measured at baseline and after 12-weeks. Baseline values of the oxidative stress markers did not differ significantly between the two groups. In cases, after three months treatment, there was a significant reduction in AOPP (137.52 +/- 25.59, 118.45 +/- 38.42, p< 0.001), and AGE (69.28 +/- 4.58, 64.31 +/- 8.64, p = 0.002). FRAP and PON increased significantly (1060.67 +/- 226.69, 1347.80 +/- 251.40, p< 0.001 and 29.85 +/- 23.18, 37.86 +/- 27.60, p = 0.012 respectively). LCAT levels remained unchanged (45.23 +/- 4.95, 46.15 +/- 6.28, p = 0.439). Comparing the two groups in a final multivariate model, AOPP, FRAP, and AGE levels changed more significantly in metformin compared with lifestyle modification alone (p = 0.007, p< 0.001 and p< 0.001 respectively). Escalation in LCAT or PON activities did not differ between the two groups (p = 0.199 and 0.843 respectively)."
According to the news editors, the research concluded: "Use of metformin is more effective in reducing oxidative stress compared with lifestyle modification alone."
For more information on this research see: Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: A randomized clinical trial. Clinical Nutrition, 2013;32(2):179-185. Clinical Nutrition can be contacted at: Churchill Livingstone, Journal Production Dept, Robert Stevenson House, 1-3 Baxters Place, Leith Walk, Edinburgh EH1 3AF, Midlothian, Scotland. (Elsevier - www.elsevier.com; Clinical Nutrition - www.elsevier.com/wps/product/cws_home/623017)
The news correspondents report that additional information may be obtained from A. Esteghamati, Shahid Beheshti Univ Med Sci, Cellular & Mol Res Center, Res Inst Endocrine Sci, Tehran, Iran (see also Diet and Nutrition).
Keywords for this news article include: Iran, Asia, Antidiabetic Agents, Antioxidants, Drugs, Tehran, Therapy, Metformin, Biguanides, Non-Sulfonylureas, Protective Agents, Diet and Nutrition, Type 2 Diabetes Mellitus, Non-Insulin Dependent Diabetes Mellitus
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.